Compare Box Inc (BOX) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Citius Pharmaceuticals Inc — how do they compare? Box Inc trades at $32.86 (market cap $4.65B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Box Inc is far larger — about 248.3× Citius Pharmaceuticals Inc's market cap, and Box Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BOX | CTXR | |
|---|---|---|
Market Cap | $4.65B | $18.73M |
Sector | Technology | Health |
52-Week High | $33.60 | $1.82 |
52-Week Low | $21.37 | $0.48 |
Enterprise Value | $5.21B | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX Inc. (NYSE: BOX) trades at $33.24, up 4.36% today, showing strong momentum near resistance levels. The company delivered solid Q1 2026 earnings beat with EPS of $0.37 versus $0.36 expected, continuing positive earnings surprises. Revenue growth accelerated to $1.09 billion in 2025 with net income margin expanding to 22.43%. Technical indicators show bullish momentum with the stock trading above key support levels and moving averages signaling strength.
BOX presents growth potential with strong revenue expansion and improving profitability, supported by recent enterprise contract wins like Quintas Energy's AI platform selection. However, elevated P/E ratio of 51.94 suggests premium valuation, while negative equity and high debt levels warrant monitoring. Analyst consensus remains bullish with $37 price target, representing 11% upside from current levels.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
